Clinical Trial

Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is being done to see if combining HEPZATO KIT™ with nivolumab and relatlimab (Opdualag™) in patients with metastatic melanoma with liver metastasis is safe, tolerable, and will have a synergistic effect leading to improved clinical outcomes compared to the historic cohort of patients with liver metastasis treated with combination immune checkpoint inhibitor therapy.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2025-12-04; most recent amendment 2026-07-22.
Status change: Not Yet Recruiting → Recruiting 2026-02-02
Trial Details
NCT Number NCT07281924
Lead Sponsor University of Wisconsin, Madison
Collaborators: Delcath Systems Inc.
Conditions Metastatic Melanoma, Liver Metastases
Enrollment 15 participants
Start Date 2026-08
Primary Completion 2030-12 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-29